Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). (Q34550540)

3 August 2017

Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). (English)

1 reference

3 August 2017

1 reference

1 reference

lymphoblastic leukemia

1 reference

20

Hagop M Kantarjian

1 reference

3 August 2017

10

Alessandra Ferrajoli

1 reference

3 August 2017

Guillermo Garcia-Manero

11

object named as

Guillermo Garcia-Manero

1 reference

3 August 2017

13

Jorge E Cortes

1 reference

3 August 2017

8

Naveen Pemmaraju

1 reference

3 August 2017

7

Tapan M Kadia

1 reference

3 August 2017

12

Marina Y Konopleva

1 reference

3 August 2017

5

Elias J Jabbour

1 reference

3 August 2017

15

Rebecca Garris

1 reference

3 August 2017

9

Naval G Daver

1 reference

3 August 2017

18

Jeffrey L Jorgensen

1 reference

3 August 2017

1

Michael E Rytting

1 reference

3 August 2017

19

Steven M Kornblau

1 reference

3 August 2017

14

Gautham Borthakur

1 reference

3 August 2017

6

Anna R Franklin

1 reference

3 August 2017

Farhad Ravandi-Kashani

4

object named as

Farhad Ravandi-Kashani

1 reference

3 August 2017

3

Susan M O'Brien

1 reference

3 August 2017

Deborah A Thomas

2

1 reference

3 August 2017

Maria Cardenas-Turanzas

16

1 reference

3 August 2017

Kurt Schroeder

17

1 reference

3 August 2017

language of work or name

English

0 references

publication date

17 July 2014

1 reference

3 August 2017

1 reference

3 August 2017

120

1 reference

3 August 2017

3660-3668

1 reference

3 August 2017

23

1 reference

The treatment of adolescents and young adults with acute lymphoblastic leukemia

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Asparaginase-associated pancreatitis in children

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children's oncology group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Münster study group.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Current management and challenges of malignant disease in the CNS in paediatric leukaemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Understanding medication adherence in pediatric acute lymphoblastic leukemia: a review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Thromboembolic events in children with acute lymphoblastic leukemia (BFM protocols): prednisone versus dexamethasone administration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Profile of non-compliance in lymphoblastic leukaemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Evaluation of survival data and two new rank order statistics arising in its consideration

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4239168

Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.

7 July 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Acute lymphoblastic leukemia in adolescents and young adults in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Español de Tratamiento en Hematología pediatric-based protocol ALL-96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Prospective study on incidence, risk factors, and long-term outcome of osteonecrosis in pediatric acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28930

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

21 January 2018

1 reference

12 December 2020

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols

1 reference

12 December 2020

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

1 reference

12 December 2020

Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study

1 reference

12 December 2020

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

12 December 2020

Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials

1 reference

12 December 2020

Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience

1 reference

12 December 2020

Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment

1 reference

12 December 2020

Identifiers

DOI

10.1002/CNCR.28930

1 reference

3 August 2017

1 reference

3 August 2017

1 reference